Citations

Clear

1056 citation(s) found for "Sharma, P".

Antibody–Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management
Sharma, Ashish , Kumar, Harendra , Paladiya, Ruchir, Sisodia, Rajvardhan , Alsakarneh, Saqr, Hayat, Umar, Sonaiya, Sneh , Pinnam, Hema Sameera, Ali, Hassam, Dahiya, Dushyant Singh , Ali, Hassam , Kumar, Harendra , Pinnam, Hema Sameera , Dahiya, Dushyant Singh , Bharadwaj, Hareesha Rishab , Mohamed, Islam

Mayo Clinic

Journal of Personalized Medicine | April 1, 2026 | Volume: 16 | Issue: 4 | Pages: 195

10.3390/jpm16040195 | PMID 42042562 Get It

Antibody–drug conjugates (ADCs) are reshaping the therapeutic approach to advanced gastrointestinal cancers by integrating tumor-specific monoclonal antibodies with potent cytotoxic payloads to improve targeted tumor cell destruction while minimizing systemic exposure. Compared to traditional chemotherapy, trastuzumab deruxtecan has significantly improved objective response rates and overall survival in HER2-positive gastric and gastroesophageal junction tumors after trastuzumab-based therapy. This supports its role as an important second-line or later treatment option. The ongoing advancement of ADCs targeting CLDN18.2, TROP2, and CEACAM5 indicates that this therapeutic category will continue to expand across gastrointestinal neoplasms. Nonetheless, these advancements are accompanied by a specific and clinically significant toxicity profile. Hematologic suppression, gastrointestinal side effects, hepatotoxicity, and notably interstitial lung disease (ILD) are essential consequences that may need inpatient assessment and care. Interstitial lung disease (ILD), although uncommon, may be severe or lethal if not identified immediately and treated swiftly with medication cessation and corticosteroids. In hospitalized patients, distinguishing ADC-related toxicity from infection or disease progression is often difficult owing to overlapping clinical manifestations, requiring meticulous evaluation and interdisciplinary cooperation. As ADCs are integrated into earlier treatment lines and across a broader patient population, hospital systems must evolve to ensure prompt identification, consistent management protocols, and efficient collaboration between oncology and inpatient teams. This study analyzes the mechanisms, clinical effectiveness, and safety profile of ADCs in gastrointestinal oncology, pointing out the importance of institutional preparedness to safely incorporate these medicines into standard clinical practice. These features also align ADC therapy with personalized medicine by emphasizing biomarker-guided patient selection and individualized toxicity monitoring.
Representation of Women in Atrial Fibrillation Clinical Trials: A Systematic Review
Ibrahim, Ramzi, Pham, Hoang Nhat, Kanaan, Christopher , Alhwarat, Buthainah, Sainbayar, Enkhtsogt , Soin, Sabrina , Ayoub, Chadi, Chieffo, Alaide , Sharma, Garima , Protheroe, Jo , Lee, JC, Arsanjani, Reza, Mamas, Mamas A., Sharma, Garima , Pham, Hoang Nhat , Ibrahim, Ramzi , Ibrahim, Ramzi , Nhat, Hoang , Ayoub, Chadi , Deshmukh, Abhishek J , Arsanjani, Reza , Lee, Kwan S , Mamas, Mamas , Sharma, Garima , Kanaan, Christopher N , Ibrahim, Ramzi , Arsanjani, Reza , Lee, Kwan , Mamas, Mamas A.

Mayo Clinic

Reviews in Cardiovascular Medicine | March 31, 2026 | Volume: 27 | Issue: 3 | Pages: No page available

10.31083/rcm47907 | PMID 41923740 Get It

Background: Disparities exist in the representation of genders in cardiovascular clinical trials. Atrial fibrillation (AF) is associated with significant morbidity and mortality; however, understanding regarding the representation of women in AF-related clinical trials remains limited. Therefore, this systematic review sought to evaluate the representation of women in AF-related clinical trials. Methods: We conducted a systematic review of clinical trials using the PubMed, Scopus, and EMBASE databases from 1996 to January 1st, 2024, focusing on AF-related lifestyle interventions, pharmacological treatments, catheter ablation, and device therapies for AF. Data extraction and analysis encompassed trial characteristics, participant demographics, and funding sources. The primary outcome was the prevalence of female enrollees, quantified through participation-to-prevalence ratios (PPRs). This was estimated overall and stratified by funding source, intervention type, and enrollment region. Results: Of the 103 clinical trials involving 218,322 participants (39.5% female), the PPR ranged from 0.00 to 1.73, with an average PPR of 1.03. Meanwhile, 43% of the trials exhibited female under-representation (PPR, <0.8). University-funded trials showed higher female enrollment (mean PPR, 0.951) compared to industry/government-funded trials (mean PPR, 0.800). No differences were observed in the representation of women when comparing enrollment regions or intervention types. Conclusions: Despite advancements in AF management, gender disparities persist in AF-related clinical trial representation, particularly in industry/government-funded studies compared to university-funded trials. Thus, addressing implicit biases and enforcing sex equality guidelines are critical steps toward more inclusive cardiovascular research.
A Retrospective Study of Long-Term Associations of Behavioral Intervention Combined with Medications in Young Children with Attention-Deficit/Hyperactivity Disorder
Price, Taylor, Bommersbach, Tanner J. , Saliba, Maria , Kelly, Casey K., Tarikogullari, Idil , Romanowicz, Magdalena , Romanowicz, Magdalena , LeMahieu, Allison , Sharma, Pravesh , Abulseoud, Osama A.

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | March 28, 2026 | Volume: 36 | Issue: 3 | Pages: 128-135

10.1177/10445463261426290 | PMID 41902630 Get It

Objective: This study aimed to examine whether parent–child interaction therapy (PCIT), compared with other therapy modalities, was associated with differences in substance use and psychiatric outcomes in a cohort of children with attention-deficit/hyperactivity disorder (ADHD). Methods: This retrospective cohort study was conducted using medical record data from the Rochester Epidemiology Project (REP). The sample included 643 children aged ≤7 years who were diagnosed with ADHD and received either stimulant or nonstimulant medication, along with psychosocial therapy. Participants were categorized into two groups: those who documented exposure to PCIT versus other therapy modalities such as behavioral management, play therapy, cognitive behavioral therapy, parent management training, occupational therapy, speech therapy, parenting class, applied behavior analysis, and social skills training. Conditional logistic regression models were used to examine differences in baseline characteristics and outcomes between the two treatment groups. Results: Individuals in the PCIT group were more likely to have private insurance (66% vs. 57%; p = 0.016) and to fall into higher socioeconomic status quartiles ( p = 0.024) at baseline. PCIT recipients also had a higher prevalence of emotional and behavioral disturbances at baseline (40% vs. 25%; p < 0.001). The median age of the participants at follow-up was 19.6 years, indicating a median follow-up period of approximately 13 years from the initiation of treatment. At follow-up, the PCIT group demonstrated higher rates of problematic alcohol (24% vs. 17%; HR = 1.50, 95% CI: [1.02, 2.20]; p = 0.038) and cannabis use (25% vs. 18%; HR = 1.48, 95% CI: [1.03, 2.15]; p = 0.037). However, after controlling for covariates in the adjusted model, no statistically significant differences emerged between the groups across any substance use outcome. No significant differences were observed in other psychiatric diagnoses or mental health service utilization. Conclusions: Findings indicate that individuals who documented exposure to PCIT demonstrated elevated rates of alcohol and cannabis use in young adulthood, but had no other differences in psychiatric outcomes. While this aligns with prior literature reporting increased substance use risk in ADHD populations, our study cannot confirm this association relative to non-ADHD controls because such a comparison was not included. These associations likely reflect underlying differences in clinical severity and clinical comorbidities at baseline, rather than a direct effect of PCIT. Further investigation is warranted to determine the treatment effects based on baseline risk factors.
Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts
Kendrick, J. Richard, Ahmad, Ghonwa, Wood, Audrey, Stumo, Samuel , Sehgal, Aarav, Matthews, Douglas B. , Sharma, Pravesh , Sharma, Pravesh , Matthews, Douglas B , Kendrick, Jared

Mayo Clinic

Behavioral Sciences | March 25, 2026 | Volume: 16 | Issue: 4 | Pages: 480

10.3390/bs16040480 | PMID 42073843 Get It

The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders across six domains: perceived positive effects, adverse effects, reasons for use, route of administration, polydrug use, and dose amounts. Mood-related concerns were the primary reason for use (53%). Users reported positive effects, most often improvements in emotional well-being (65%). Adverse effects were predominantly psychological or mood-related (56%). A total of 70% of reported doses exceeded 149 mg, suggesting a trend toward higher dose use. Intravenous administration (40%) and sublingual troches (23%) were the most frequently reported routes. Concurrent use of prescribed psychotropics, cannabis, and psychedelics was also reported. This analysis identified substantial heterogeneity in individual-reported experiences. Frequent high-dose use, dose escalation, and polydrug exposure underscores the importance of clinical monitoring and attention to addiction potential and drug–drug interactions. The findings should be interpreted with caution, as follow-up and clinical verification were not possible; however, the data provide an unfiltered view of individual experiences in relation to ketamine use outside the clinical setting.
Expanding the molecular grading criteria in IDH-mutant astrocytoma
Virata, Michael , Samanamud, Jorge , Slocum, Connie, Kandoi, Shrishtee , Nguyen, Phuong , Savani, Milan R. , Shi, Diana D, Sharma, Sachein , Hiya, Satomi , Maldonado-Díaz, Carolina , Clare, Kevin, Vij, Meenakshi, Mir, Ema, Nishikawa, Y , Umphlett, Melissa , Yong, Raymund L. , Bederson, Joshua B. , Silva-Hurtado, Thenzing J. , Brem, Steven, Hambardzumyan, Dolores, Snuderl, Matija, Viapiano, Mariano S. , McBrayer, Samuel K. , Hatanpaa, Kimmo J. , Tsankova, Nadejda M. , Richardson, Timothy E. , Virata, Michael Christian , Samanamud, Jorge , Nguyen, Phuong , Yokoda, Raquel T , Vij, Meenakshi , Mir, Ema , Yong, Raymund L , Silva-Hurtado, Thenzing J , Brem, Steven , Hambardzumyan, Dolores , Snuderl, Matija , Viapiano, Mariano S , Abdullah, Kalil G , McBrayer, Samuel K , Tsankova, Nadejda M , Richardson, Timothy E , Shi, Diana D. , Yokoda, Raquel T. , Snuderl, Matija , Walker, Jamie M.

Mayo Clinic

Neuro-Oncology | March 24, 2026 | Volume: 28 | Issue: 8 | Pages: 1921-1932

10.1093/neuonc/noag069 | PMID 41903203 Get It

Abstract Background IDH-mutant astrocytomas are classified as WHO grade 4 in the presence of conventional high-grade histologic features and/or homozygous CDKN2A/B deletion in the 5th edition of the WHO Classification of Central Nervous System Tumour guidelines. However, work over the past decade has indicated a number of other molecular alterations that warrant consideration as potential prognostic markers. Methods We used univariate Kaplan-Meier and multivariate Cox proportional hazards regression analysis to evaluate the prognostic effects of homozygous CDKN2A/B deletion, CDK4 amplification, CCND2 amplification, PDGFRA amplification/mutation, PIK3R1 mutation, PIK3CA mutation, MYCN amplification, EGFR amplification/mutation, TERT promoter mutation, and grade 4 histologic features in two independent cohorts of WHO grade 2-4 IDH-mutant astrocytoma (n = 840 and n = 367). Results The presence of CDK4 amplification, CCND2 amplification, PDGFRA alteration, PIK3R1 mutation, MYCN amplification, and EGFR alteration were each associated with reduced overall survival compared to WHO grade 2/3 astrocytomas without these molecular features. 17.7% (148/837) of otherwise grade 2/3 astrocytomas had one or more of these molecular criteria, with resulting intermediate clinical outcome in terms of overall survival (median survival of 67.3-82.0 months) compared to grade 2/3 astrocytomas without these molecular features (median survival of 135.0-140.7 months) and grade 4 astrocytomas (median survival of 35.3-45.0 months). Conclusions The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
Barriers, Facilitators, and Attitudes Toward Telemedicine Adoption in Oncology: A Qualitative Study of Patients From Low-Broadband Areas
Sharma, Pravesh , Kamath, Celia , Jeno, Sarah E., Breutzman, Emily, Brockman, Tabetha A. , Haddad, Tufia C. , Pritchett, Joshua C. , Sharma, Pravesh , Kamath, Celia C , Breutzman, Emily N., Patten, Christi A. , Haddad, Tufia C , Pritchett, Joshua , Brockman, Tabetha A

Mayo Clinic

JCO Oncology Practice | March 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-01155 | PMID 41861270 Get It

PURPOSE Limited access to high-speed internet (broadband [BB]) may pose challenges to video telehealth visit (VTV) utilization. This study explored barriers, facilitators, and attitudes toward VTV adoption in patients with cancer residing in low-BB settings. METHODS We examined a cohort of patients with cancer receiving longitudinal care at Mayo Clinic Cancer Practice in the Upper Midwest. Eligible patients had ≥6 in-person visits during July 2020-October 2022, received oncology care at Mayo Clinic sites, were alive at sampling, and resided in low-BB areas defined by Federal Communications Commission data as 0 or 1 internet service provider offering <25 Mbps. We enrolled 24 participants stratified into two groups: (1) Transitioned users (TUs): adopted VTVs postpandemic (November 2022-December 2023); (2) persistent nonusers (PNUs): received exclusively in-person visits. Semistructured telephone interviews were conducted in June 2024 and thematically analyzed. RESULTS The average age of participants was 71.3 years (range, 42-88), 50% was female, and all identified as White. Three themes emerged: (1) Structural and clinical constraints—physical examinations, laboratory testing, and chemotherapy administration were viewed as requiring in-person care, whereas VTVs were perceived acceptable for routine follow-ups; (2) Skills and experience—digital literacy was generally adequate, but confidence and direct exposure to VTV distinguished TU from PNU; (3) Motivations—both groups preferred in-person care for cancer-related emotional reassurance. TU cited weather, travel burden, and proactive provider offering as adoption triggers, whereas PNU reported that VTV was rarely offered. TU focused on system-level solutions, whereas PNUs preferred individual-level resources. CONCLUSION Differential VTV adoption in low-BB settings reflected exposure, provider offering, and situational necessity rather than BB access alone. Oncology practices should consider normalizing the hybrid care model combining in-person and video appointment visits and provide tailored supports to advance equitable telemedicine. Expanding video care in oncology requires more than digital access and depends on patient experience, care context, and human connection inherent in oncology care.
Aged female and male C57BL/6J mice have reduced alcohol self-administration and altered acute alcohol withdrawal compared to younger animals
Matthews, D.L., Riley, Aidan, Staebell, Lydia, Kendrick, J. Richard, Hartwig, Jadyn , Feller, S M, Kendrick, Jared, Sharma, Pravesh

Mayo Clinic

Frontiers in Aging Neuroscience | March 19, 2026 | Volume: 18 | Issue: No issue available | Pages: No page available

10.3389/fnagi.2026.1792513 | PMID 41938068 Get It

Introduction As the age of the world’s population continues to increase it is important to investigate behaviors, such as alcohol consumption, that may negatively impact the health of the older population. Materials In the present study, aged, young adult and adolescent female and male C57BL/6J mice underwent a measure of acute alcohol withdrawal via a handling induced convulsion study followed by a drinking in the dark procedure to measure alcohol self-administration. Results We report that aged animals enter acute alcohol withdrawal later than younger animals as measured by later onset of handling induced convulsions. The later onset is likely due to reduced alcohol metabolism. Furthermore, aged animals consumed significantly less alcohol in the drinking in the dark paradigm but had similar blood alcohol concentrations compared to younger animals. Discussion The current work demonstrates for the first time differential alcohol self-administration and acute alcohol withdrawal in aged animals compared to younger animals.
The Effect of Physical Activity on the Gut Microbiome in Prediabetes: Results From a Randomized Controlled Trial
Avenido, Francis Ryan R., Mitchell, N. Reed, Hubbard, Paige F. Richmond, Johnson, Stephen, Sharma, Shweta, McDonough, Daniel J. , Rydell, Sarah A. , Pereira, Mark, Pereira, Mark A. , Sharma, Shweta , McDonough, Daniel J , Pereira, Mark A , Demmer, Ryan T. , Pope, Zachary , Avenido, Francis Ryan, Johnson, Stephen, Johnson, Abigail J.

Mayo Clinic

Diabetes Obesity and Cardiometabolic CARE | March 16, 2026 | Volume: 1 | Issue: 2 | Pages: 219-229

10.2337/doc25-0067 | PMID 42577916 Get It

OBJECTIVE To test the effect of physical activity on the gut microbiome and circulating short-chain fatty acids (SCFAs) among sedentary adults with prediabetes and overweight or obesity. RESEARCH DESIGN AND METHODS In a pilot and feasibility trial, we randomized 77 adults with prediabetes and a sedentary lifestyle into one of two groups: 1) intervention: invited to engage in home-based moderate-intensity walking 3×/week for 30 min/session in weeks 1–4 and for 45 min/session during weeks 5–8 of the 8-week intervention; or 2) control: maintained habitual physical activity levels. We performed metagenomic sequencing from stool collected at baseline, week 4, and week 8, with SCFAs measured from serum collected at baseline and week 8. Taxonomic and functional profiling was performed on the metagenomic reads; α-diversity metrics were subsequently derived. Linear regression assessed the difference in change between the intervention and control groups for α-diversity and SCFA levels. RESULTS We screened 1,533 participants for eligibility and consented 132. Of these, 87 entered the run-in phase, and 77 were randomized. Participants were mean (SD) 51.4 (8.9) years old, 87.7% female, and 74% non-Hispanic White. Mean fasting glucose was 103.3 (13.2) mg/dL, while mean BMI was 34.4 (5.7) kg/m2. Compared with the control group, the intervention group experienced decreased α-diversity as characterized by Shannon, Richness, and Faith diversity indices by intervention week 8 (P &lt; 0.05). Changes in SCFA levels were not statistically significant different in intervention versus control. CONCLUSIONS Randomization to a walking intervention resulted in modest gut microbiome changes among adults with overweight or obesity and prediabetes.
Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial
Rasheed, Azgar Abdul , Ganguly, Shuvadeep, Singh, Manraj, Sreenivas, Vishnubhatla , Pillai, Ashwati S., Joison, Anu Theresa, Sharma, Swetambri , Bakhshi, Sameer , Singh, Manraj , Sra, Manraj Singh , Ganguly, Shuvadeep , Kumar, Santhosh E. , Batra, Atul , Pushpam, Deepam

Mayo Clinic

Pediatric Blood & Cancer | March 13, 2026 | Volume: 73 | Issue: 5 | Pages: No page available

10.1002/1545-5017.70171 | PMID 41823195 Get It

ABSTRACT Background Fosaprepitant is non‐inferior to aprepitant in adults receiving highly emetogenic chemotherapy (HEC). We evaluated whether fosaprepitant is non‐inferior to aprepitant in children receiving HEC. Methods In this open‐label, non‐inferiority trial, children aged 5–18 years, receiving their first cycle of HEC, were randomized 1:1 to the fosaprepitant or aprepitant group. The fosaprepitant group received a single intravenous dose of 4 mg/kg (max 150 mg). The aprepitant group received oral aprepitant capsules (weight 15 to <30 kg: 80 mg Days 1–3; weight ≥30 kg, or age ≥12 years: 125 mg Day 1, 80 mg Days 2 and 3). Both groups received ondansetron and dexamethasone. The primary outcome was the complete response (CR) rate of vomiting during the acute phase (AP) with a non‐inferiority margin of 15%. Secondary outcomes included CR rates in the delayed (DP) and overall phases (OP), grade of vomiting, incidence and severity of nausea, and adverse effects. Results A total of 279 children were included in the modified intention‐to‐treat analysis (fosaprepitant group: 140; aprepitant group: 139). In AP, the difference of CR rate between fosaprepitant [76 (54.3%)] and aprepitant groups [84 (60.4%)] was −6.1% [90% CI: −15.7% to +3.6%], with the lower limit exceeding −15%, failing to establish non‐inferiority. The CR rate with fosaprepitant versus aprepitant was 62.1% ( n = 87) versus 65.5% ( n = 91) in DP (difference: –3.4%; 90% CI: –12.7% to 6.1%) and 42.9% ( n = 60) versus 49.6% ( n = 69) in the OP (difference: –6.7%; 90% CI: –16.5% to 3.1%). Grade of vomiting, incidence and severity of nausea, and adverse effects were similar between the two groups. Conclusions Non‐inferiority of fosaprepitant compared to aprepitant was not demonstrated in children undergoing their first cycle of HEC. Trial Registration Clinical Trials Registry, India (CTRI/2019/05/019082).
Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions
Cucchiara, Brett , Connors, Jean M. , Rabinstein, Alejandro A. , Sharma, Mukul , Cucchiara, Brett L , Rabinstein, Alejandro A

Mayo Clinic

Stroke | March 13, 2026 | Volume: 57 | Issue: 5 | Pages: 1439-1449

10.1161/strokeaha.125.054846 | PMID 41822978 Get It

Antithrombotic therapy plays an important role in reducing stroke recurrence. For noncardioembolic stroke, multiple trials have demonstrated the efficacy of antiplatelet monotherapy for secondary stroke prevention. In select situations, such as short-term treatment in the acute period after a minor stroke or transient ischemic attack, dual-antiplatelet therapy has demonstrated superiority to monotherapy. Multiple trials have tested more aggressive strategies using long-term combination antiplatelet medications or full-dose anticoagulation with limited evidence of a reduction in ischemic events but a relatively consistent increased risk of bleeding. Emerging new agents targeting factor XI/XIa may uncouple necessary hemostasis from pathological thrombosis and offer promise for enhancing secondary prevention of stroke without increasing bleeding. The recently positive OCEANIC-STROKE trial (Oral Factor Eleven A Inhibitor Asundexian as Novel Antithrombotic) testing dual-pathway inhibition with the factor XIa inhibitor asundexian in combination with antiplatelet therapy represents a major advance in antithrombotic therapy for noncardioembolic stroke. This review summarizes the current state of the evidence for antithrombotic therapy in secondary stroke prevention after noncardioembolic stroke and discusses completed and ongoing trials of novel factor XI/XIa inhibitors for stroke prevention.